重组人可溶性血栓调节蛋白与急性胰腺炎合并弥散性血管内凝血患者院内死亡率:日本全国性研究
该研究基于日本诊断程序组合全国住院数据库,纳入2010年7月至2022年3月因急性胰腺炎合并DIC住院、存活至少3天的成人患者。共10,238例,其中2,001例(19.5%)在入院3天内接受rTM,8,237例(80.5%)未接受。倾向评分匹配后得到1,868对均衡配对,rTM组院内死亡率为15.5%(290/1,868),非rTM组为19.7%(368/1,868),风险差-4.2%(95%CI -6.6%至-1.7%),风险比0.79(95%CI 0.69至0.91)。结论认为急性胰腺炎合并DIC患者使用rTM与院内死亡率降低相关。
要点
- 急性胰腺炎合并DIC成人患者入院3天内使用rTM,倾向评分匹配后院内死亡率15.5%(290/1,868)vs 未使用组19.7%(368/1,868),RR 0.79(95%CI 0.69-0.91)。
- 风险差为-4.2%(95%CI -6.6%至-1.7%),rTM组院内死亡率较低。
- 研究为日本全国性倾向评分匹配回顾性队列,纳入2010年7月至2022年3月存活至少3天的成人急性胰腺炎合并DIC患者。
- 共10,238例患者中2,001例(19.5%)接受rTM,8,237例(80.5%)未接受;匹配后每组1,868例。
- 作者结论认为rTM与院内死亡率降低相关,但研究设计为回顾性队列,关联性不等于因果关系。
适用人群与场景
- 成人急性胰腺炎合并DIC住院患者,纳入时间为2010年7月至2022年3月,且存活至少3天。
- 数据来源为日本诊断程序组合全国住院数据库。
研究设计与关键结果
- 研究类型:全国性倾向评分匹配回顾性队列研究,使用日本诊断程序组合全国住院数据库。
- 纳入10,238例急性胰腺炎合并DIC成人患者,其中2,001例(19.5%)在入院3天内接受rTM,8,237例(80.5%)未接受。
- 倾向评分匹配后得到1,868对均衡配对;rTM组院内死亡率15.5%(290/1,868),非rTM组19.7%(368/1,868)。
- 风险差-4.2%(95%CI -6.6%至-1.7%),风险比0.79(95%CI 0.69至0.91)。
证据类型、等级与局限
- 证据类型:全国性倾向评分匹配回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,急性胰腺炎合并DIC患者使用rTM与院内死亡率降低相关;该结论来自回顾性队列的关联分析。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Acute pancreatitis (AP) complicated by disseminated intravascular coagulation (DIC) is associated with high mortality. Although recombinant human soluble thrombomodulin (rTM) is commonly used in clinical practice, its association with outcomes in AP has not been established.
DESIGN: A nationwide, propensity score-matched, retrospective cohort study.
SETTING: The Japanese Diagnosis Procedure Combination national inpatient database.
PATIENTS: Adult patients hospitalized with AP and DIC between July 2010 and March 2022, who survived at least 3 days. Patients were divided into those receiving rTM within three days of admission and those who did not. Propensity score matching compared in-hospital mortality.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The analysis included 10,238 patients with AP and DIC, of whom 2,001 (19.5%) received rTM and 8,237 (80.5%) did not. Propensity score matching yielded 1,868 well-balanced pairs. In-hospital mortality was lower in the rTM group (15.5% [290/1,868]) compared with the non-rTM group (19.7% [368/1,868]; risk difference: -4.2%, 95% CI, -6.6% to -1.7%; risk ratio: 0.79, 95% CI, 0.69 to 0.91).
CONCLUSIONS: Administration of rTM in patients with AP complicated by DIC was associated with lower in-hospital mortality.
参考来源
- Okada H, Horibe M, Sasabuchi Y, et al. Recombinant Human Soluble Thrombomodulin and In-Hospital Mortality in Acute Pancreatitis With Disseminated Intravascular Coagulation: A Japanese Nationwide Study. Crit Care Med. 2026. PMID: 41489428. doi:10.1097/CCM.0000000000007009
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。